Up Approx. 28%, Low Float (Nasdaq: NTRB) Surges On A New Shareholder Letter This AM

Nutriband Inc. (Nasdaq: NTRB) is making moves early Wednesday.

*Sponsored by Nutriband Inc. Up Approx. 28%, Low Float (Nasdaq: NTRB) Surges On A New Shareholder Letter This AM  April 30th Dear Reader, Nutriband Inc. (Nasdaq: NTRB) is making moves early Wednesday. Currently up approx. 28%, NTRB just dropped a key shareholder letter this morning. Check it out: Nutriband CEO Publishes Letter to Shareholders On top of the letter, it's important to remember that NTRB is a low float idea with fewer than 6Mn shares in its float. Even more, NTRB has a $13 analyst target suggesting it may have serious upside potential from current levels. Take a quick moment to review the initial (Nasdaq: NTRB) report below and consider this breakout idea for your radar. ----- Let's get after it, but first, a quick recap. We could be on the front end of a heater, as my last two profiles have gone on strong runs. Brought into focus on Sunday night, my latest Nasdaq idea hit the ground running after closing in after hours at $3.50 this past Friday. Reaching a high of $4.4299 after Monday's opening bell, that low float idea blazed a move of approximately 26% short term. And that comes after last week's profile that ran from an after hours close of $.7931, to a high of $1.42 the following morning for an approximate vertical chart rip 79%. Back-to-back breakouts totaling a combined 105% short term! And it chaotic markets! But we're not here to pat ourselves on the back. We're here to deliver a new breakout idea. And this one could be a doozy... With a low float under 6Mn shares, an analyst $13 target suggesting significant upside potential, and several recent press releases highlighting a company making strategic moves to help earn them global recognition, it may be the perfect time to consider this Nasdaq profile for your watchlist. Oh, and not to pour it on, but this little firecracker recently rattled off an incredible two-day move of $7.50+ in January and has already put together a run of 45+% from April lows to this week's highs. Now, that's not to say any move will happen like that again, but with all the potential catalysts shared above, now could be the time to consider taking a look at: *Nutriband Inc. (Nasdaq: NTRB)* Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse-deterrent fent-a-nyl patch incorporating their AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on several potential breakout catalysts, NTRB has risen to the top spot on my watchlist: #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. #4. Nutriband Receives Certificate Of Registration For Trademark "Integral" To The Commercialization Of Company's Platform Tech. #5. An Exclusive Development Partnership Gets Formalized With Kindeva Drug Delivery. But more on those in a second... Full Company Breakdown: Nutriband Inc. (Nasdaq: NTRB) Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Their model is to apply Transdermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. The company's first product and lead platform technology is AVERSA, an abuse deterrent tech which is applicable to any patch on the market today. According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. The company has 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products. Nutriband is earning revenues to keep their development burn at a minimum. They also own their own manufacturing and clinical development capabilities which drastically reduces their costs for AVERSA and other technologies. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline Sources: NTRB Website. NTRB Presentation. ----- As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now: #1. NTRB Potential Catalyst - A $13 Analyst Target Suggests Substantial Upside Potential! Back in February, an analyst Noble Capital Markets reiterated a $13 target for NTRB. From NTRB's opening valuation Tuesday, that target suggested over 100% potential upside. Here's some key report highlights: There Are Important Milestones In The Coming Months. We expect the st-ock to be driven by clinical milestones from the AVERSA Fent-a-nyl pathway to the NDA submission and product approval. The Phase 1 abuse deterrence trial is expected to start in 1H25, with results expected in 2H25. This could be followed by an NDA submission in late 2025 to early 2026.  Conclusion. As discussed in our Initiation of Coverage Report on January 22, we believe AVERSA Fent-a-nyl can be the first abuse-deterrent transdermal fent-a-nyl patch. Our revenue projections are based on the lower risk of abuse or misuse leading to AVERSA Fent-a-nyl taking market share from the current generic transdermal patches. The additional safety from the abuse-deterrent technology could potentially grow the market and drive upward revisions to our estimates. We are reiterating our Outperform rating and $13 price target. ----- #2. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily). According to info from the Yahoo Finance website, NTRB has a pretty low float. The website reports this profile to have roughly 5.11Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- #3. NTRB Potential Catalyst - A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. UPDATE – Nutriband Signs Associate Partnership with Charlotte FC ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. “We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.’’ AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina. The Company also intends to use the relationship to promote its platform technology AVERSA and raise awareness for the technology which has the potential to be the World’s first and only abuse deterrent patch platform for managing chronic pain. Read the full article here. ----- #4. NTRB Potential Catalyst - Nutriband Receives Certificate Of Registration For Trademark "Integral" To The Commercialization Of Company's Platform Tech. Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development. ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™." The Trademark registration covers Goods/Services: Class: 042 Product research and development, scientific research and development; biochemical research and development; pharmaceutical research and development. The Nutriband™ trademark is integral to the commercialization of the Company’s platform technology AVERSA which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under development is AVERSA™ Fent-a-nyl, an abuse deterrent fent-a-nyl transdermal system. ... Read the full article here. ----- #5. NTRB Potential Catalyst - An Exclusive Development Partnership Gets Formalized With Kindeva Drug Delivery. Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fent-a-nyl Abuse Deterrent Fent-a-nyl Patch Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fent-a-nyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fent-a-nyl patch. ORLANDO, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa™ Fent-a-nyl, that it has in place with its partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products. Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. ... Read the full article here. ----- (Nasdaq: NTRB) Potential Catalyst Recap - The Top 5 To Consider Right Now #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. #4. Nutriband Receives Certificate Of Registration For Trademark "Integral" To The Commercialization Of Company's Platform Tech. #5. An Exclusive Development Partnership Gets Formalized With Kindeva Drug Delivery. ----- Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). I'll be in touch with updates when necessary. Talk again soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/29/2025 and ending on 04/30/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither SWN Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/ntrb-ybhl5/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice